Deciphex Limited – Trademark Portfolio
Entity Type: 99
Deciphex Limited holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include DIAGNEXIA, D DECIPHEX, PATHOLYTIX, and PATHOLYTIX PRECLINICAL.
Invent, DCU
Dublin 9 0000
Showing of trademarks Trademarks
Trademark Classifications
Deciphex Limited's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Deciphex Limited have?
Deciphex Limited has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Deciphex Limited file in?
Deciphex Limited files trademarks across 4 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 44 (Medical Services), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Deciphex Limited's most well-known trademarks?
Deciphex Limited's registered trademark portfolio includes well-known marks such as DIAGNEXIA, D DECIPHEX, PATHOLYTIX, and PATHOLYTIX PRECLINICAL. These are among 4 currently registered trademarks in the portfolio.
What is Deciphex Limited's trademark registration success rate?
Deciphex Limited has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.